However, a study published by Matsuura et al. confirmed that ALK rearrangement was a more favourable biomarker for cancer-specific survival (CSS) and OS than non-ALK rearrangement in resected NSCLC [32]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.